REG - Oxford Biomedica PLC - Grant of options
03/05/2022 17:30
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220503:nRSC1810Ka&default-theme=true
RNS Number : 1810K Oxford Biomedica PLC 03 May 2022
Grant of options
London, UK - 03 May 2022: Oxford Biomedica plc ("Oxford Biomedica" or "the
Company") (LSE: OXB) announces that on 29 April 2022 nil-cost share options
over ordinary shares of 50 pence each in the Company were granted under the
Oxford Biomedica 2015 Deferred Bonus Plan ("DBP") and the Oxford Biomedica
2015 Long Term Incentive Plan ("LTIP").
2022 LTIP and 2021 DBP Awards
Name of individual Title Number of shares subject to the 2021 DBP award Number of shares subject to the 2022 LTIP award Total shares over which options now held Percentage of current issued share capital under option
John Dawson Chief Executive Officer until 28 January 2022 52,118 - 827,669 0.9%
Stuart Paynter Chief Financial Officer 35,171 96,100 347,623 0.4%
Dave Backer Chief Commercial Officer 5,082 (1) 47,197 69,213 0.07%
Tim Kelly Chief Executive Officer of OXB Solutions - 38,528 191,305 0.2%
Lisa James Chief People Officer - 26,376 44,432 0.05%
James Miskin Chief Technical Officer 16,168 38,135 181,357 0.2%
Kyriacos Mitrophanous Chief Scientific Officer 16,321 38,501 198,510 0.2%
Nicholas Page Chief Operations Officer 17,381 40,261 157,464 0.2%
Madduri Ravi Rao Chief Medical Officer - 28,318 60,136 (2) 0.06%
Jason Slingsby Chief Business Officer 15,458 36,466 129,188 0.1%
Matthew Treagus Chief Information Officer 5,314 38,501 56,412 0.06%
Natalie Walter General Counsel 14,008 32,268 102,858 0.1%
Alex Lewis Chief of Staff - 9,423 (3) 78,650 0.08%
(1) Dave Backer's DBP award were granted under the 2015 LTIP scheme as opposed
to the 2015 Deferred Bonus Plan (DBP) due to US tax considerations and
California regulatory considerations.
(2) Dr. Madduri Rao's RSU joining options (see below) are included in this
figure.
Under the terms of the DBP plan, the DBP awards will become exercisable as to
one third of the shares subject to each award on each of the first three
anniversaries of the grant date.
In line with best practice and current investor guidance the quantum of the
2022 LTIP to Stuart Paynter was scaled back from 175% of salary to 155% of
salary. The quantum of 2022 LTIP granted to other members of SET was scaled
back in line with Stuart Paynter's scale back percentage.
John Dawson did not received an award under the LTIP scheme for 2022.
The LTIP awards are subject to performance conditions. As set out in the 2021
Directors' Remuneration Report, the performance condition is based on TSR (40%
of the award, assessed over the three years from grant); revenue growth (40%
of the award, assessed over financial years 2022, 2023 and 2024) and strategic
milestones (20% of the award). Details of the measures are included in the
2021 Directors' Remuneration Report, other than as regards the strategic
milestones, which are commercially sensitive and will be disclosed in due
course.
The LTIP awards granted Stuart Paynter will "vest" following the assessment of
the performance condition, but will only be "released" so that they can be
exercised following the end of a further two year holding period. The 2022
awards granted to other participants will vest and be released following the
assessment of the performance condition.
RSU awards
(3) In addition, on 29 April 2022 a nil-cost share option over 9,423 shares of
50 pence each in the Company was also granted under the LTIP scheme to
Alexander Lewis, Chief of Staff.
As joining shares, a nil-cost share option over 31,818 shares of 50 pence each
in the Company was also granted under the LTIP scheme to Dr Madduri Rao.
The RSU awards are not subject to performance conditions and will become
exercisable from the third anniversary of the grant date.
The Notification of Dealing Forms set out below are provided in accordance
with the requirements of the EU Market Abuse Regulation.
Notification of Dealing Form
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
a) Name John Dawson
2. Reason for the notification
a) Position/status Chief Executive Officer
b) Initial notification/ Initial Notification
amendment
3. Details of the Issuer
a) Name Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of 50 pence each
Identification code ISIN: GB00BDFBVT43
b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Deferred Bonus
Plan. No consideration was paid for the grant of awards.
c) Price(s) and volumes(s) 2022 LTIP Award
Price Volume
Nil Nil
2021 DBP Award
Price Volume
Nil 52,118
d) Aggregated information
- Aggregate volume Awards granted over 52,118 shares in total
- Price
N/A
e) Date of the transaction 2022-04-29
f) Place of the transaction Outside of trading venue
2021 DBP Award
Price Volume
Nil 52,118
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 52,118 shares in total
N/A
e)
Date of the transaction
2022-04-29
f)
Place of the transaction
Outside of trading venue
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
a) Name Stuart Paynter
2. Reason for the notification
a) Position/status Chief Financial Officer
b) Initial notification/ Initial Notification
amendment
3. Details of the Issuer
a) Name Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of 50 pence each
Identification code ISIN: GB00BDFBVT43
b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive
Plan and Deferred Bonus Plan. No consideration was paid for the grant of
awards.
c) Price(s) and volumes(s) 2022 LTIP Award
Price Volume
Nil 96,100
2021 DBP Award
Price Volume
Nil 35,171
d) Aggregated information
- Aggregate volume Awards granted over 131,271 shares in total
- Price
N/A
e) Date of the transaction 2022-04-29
f) Place of the transaction Outside of trading venue
2021 DBP Award
Price Volume
Nil 35,171
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 131,271 shares in total
N/A
e)
Date of the transaction
2022-04-29
f)
Place of the transaction
Outside of trading venue
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
a) Name Dave Backer
2. Reason for the notification
a) Position/status Chief Commercial Officer
b) Initial notification/ Initial Notification
amendment
3. Details of the Issuer
a) Name Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of 50 pence each
Identification code ISIN: GB00BDFBVT43
b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive
Plan and Deferred Bonus Plan. No consideration was paid for the grant of
awards.
c) Price(s) and volumes(s) 2022 LTIP Award
Price Volume
Nil 47,197
2021 DBP Award
Price Volume
Nil 5,082
d) Aggregated information
- Aggregate volume Awards granted over 52,279 shares in total
- Price
N/A
e) Date of the transaction 2022-04-29
f) Place of the transaction Outside of trading venue
2021 DBP Award
Price Volume
Nil 5,082
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 52,279 shares in total
N/A
e)
Date of the transaction
2022-04-29
f)
Place of the transaction
Outside of trading venue
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
a) Name Tim Kelly
2. Reason for the notification
a) Position/status Chief Executive Officer of OXB Solutions
b) Initial notification/ Initial Notification
amendment
3. Details of the Issuer
a) Name Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of 50 pence each
Identification code ISIN: GB00BDFBVT43
b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive
Plan. No consideration was paid for the grant of awards.
c) Price(s) and volumes(s) 2022 LTIP Award
Price Volume
Nil 38,528
2021 DBP Award
Price Volume
Nil Nil
d) Aggregated information
- Aggregate volume Awards granted over 38,528 shares in total
- Price
N/A
e) Date of the transaction 2022-04-29
f) Place of the transaction Outside of trading venue
2021 DBP Award
Price Volume
Nil Nil
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 38,528 shares in total
N/A
e)
Date of the transaction
2022-04-29
f)
Place of the transaction
Outside of trading venue
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
a) Name Lisa James
2. Reason for the notification
a) Position/status Chief People Officer
b) Initial notification/ Initial Notification
amendment
3. Details of the Issuer
a) Name Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of 50 pence each
Identification code ISIN: GB00BDFBVT43
b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive
Plan. No consideration was paid for the grant of awards.
c) Price(s) and volumes(s) 2022 LTIP Award
Price Volume
Nil 26,376
2021 DBP Award
Price Volume
Nil Nil
d) Aggregated information
- Aggregate volume Awards granted over 26,376 shares in total
- Price
N/A
e) Date of the transaction 2022-04-29
f) Place of the transaction Outside of trading venue
2021 DBP Award
Price Volume
Nil Nil
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 26,376 shares in total
N/A
e)
Date of the transaction
2022-04-29
f)
Place of the transaction
Outside of trading venue
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
a) Name James Miskin
2. Reason for the notification
a) Position/status Chief Technical Officer
b) Initial notification/ Initial Notification
amendment
3. Details of the Issuer
a) Name Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of 50 pence each
Identification code ISIN: GB00BDFBVT43
b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive
Plan and Deferred Bonus Plan. No consideration was paid for the grant of
awards.
c) Price(s) and volumes(s) 2022 LTIP Award
Price Volume
Nil 38,135
2021 DBP Award
Price Volume
Nil 16,168
d) Aggregated information
- Aggregate volume Awards granted over 54,303 shares in total
- Price
N/A
e) Date of the transaction 2022-04-29
f) Place of the transaction Outside of trading venue
2021 DBP Award
Price Volume
Nil 16,168
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 54,303 shares in total
N/A
e)
Date of the transaction
2022-04-29
f)
Place of the transaction
Outside of trading venue
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
a) Name Kyriacos Mitrophanous
2. Reason for the notification
a) Position/status Chief Scientific Officer
b) Initial notification/ Initial Notification
amendment
3. Details of the Issuer
a) Name Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of 50 pence each
Identification code ISIN: GB00BDFBVT43
b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive
Plan and Deferred Bonus Plan. No consideration was paid for the grant of
awards.
c) Price(s) and volumes(s) 2022LTIP Award
Price Volume
Nil 38,501
2021 DBP Award
Price Volume
Nil 16,321
d) Aggregated information
- Aggregate volume Awards granted over 54,822 shares in total
- Price
N/A
e) Date of the transaction 2022-04-29
f) Place of the transaction Outside of trading venue
2021 DBP Award
Price Volume
Nil 16,321
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 54,822 shares in total
N/A
e)
Date of the transaction
2022-04-29
f)
Place of the transaction
Outside of trading venue
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
a) Name Nicholas Page
2. Reason for the notification
a) Position/status Chief Operations Officer
b) Initial notification/ Initial Notification
amendment
3. Details of the Issuer
a) Name Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of 50 pence each
Identification code ISIN: GB00BDFBVT43
b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive
Plan and Deferred Bonus Plan. No consideration was paid for the grant of
awards.
c) Price(s) and volumes(s) 2022 LTIP Award
Price Volume
Nil 40,261
2021 DBP Award
Price Volume
Nil 17,381
d) Aggregated information
- Aggregate volume Awards granted over 57,642 shares in total
- Price
N/A
e) Date of the transaction 2022-04-29
f) Place of the transaction Outside of trading venue
2021 DBP Award
Price Volume
Nil 17,381
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 57,642 shares in total
N/A
e)
Date of the transaction
2022-04-29
f)
Place of the transaction
Outside of trading venue
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
a) Name Madduri Rao
2. Reason for the notification
a) Position/status Chief Medical Officer
b) Initial notification/ Initial Notification
amendment
3. Details of the Issuer
a) Name Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of 50 pence each
Identification code ISIN: GB00BDFBVT43
b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive
Plan. No consideration was paid for the grant of awards.
c) Price(s) and volumes(s) 2022 LTIP Award
Price Volume
Nil 28,318
2021 DBP Award
Price Volume
Nil Nil
2022 RSU Award
Price Volume
Nil 31,818
d) Aggregated information
- Aggregate volume Awards granted over 60,136 shares in total
- Price
N/A
e) Date of the transaction 2022-04-29
f) Place of the transaction Outside of trading venue
2021 DBP Award
Price Volume
Nil Nil
2022 RSU Award
Price Volume
Nil 31,818
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 60,136 shares in total
N/A
e)
Date of the transaction
2022-04-29
f)
Place of the transaction
Outside of trading venue
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
a) Name Jason Slingsby
2. Reason for the notification
a) Position/status Chief Business Officer
b) Initial notification/ Initial Notification
amendment
3. Details of the Issuer
a) Name Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of 50 pence each
Identification code ISIN: GB00BDFBVT43
b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive
Plan and Deferred Bonus Plan. No consideration was paid for the grant of
awards.
c) Price(s) and volumes(s) 2022 LTIP Award
Price Volume
Nil 36,466
2021 DBP Award
Price Volume
Nil 15,458
d) Aggregated information
- Aggregate volume Awards granted over 51,924 shares in total
- Price
N/A
e) Date of the transaction 2022-04-29
f) Place of the transaction Outside of trading venue
2021 DBP Award
Price Volume
Nil 15,458
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 51,924 shares in total
N/A
e)
Date of the transaction
2022-04-29
f)
Place of the transaction
Outside of trading venue
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
a) Name Matthew Treagus
2. Reason for the notification
a) Position/status Chief Information Officer
b) Initial notification/ Initial Notification
amendment
3. Details of the Issuer
a) Name Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of 50 pence each
Identification code ISIN: GB00BDFBVT43
b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive
Plan and Deferred Bonus Plan. No consideration was paid for the grant of
awards.
c) Price(s) and volumes(s) 2022 LTIP Award
Price Volume
Nil 38,501
2021 DBP Award
Price Volume
Nil 5,314
d) Aggregated information
- Aggregate volume Awards granted over 43,815 shares in total
- Price
N/A
e) Date of the transaction 2022-04-29
f) Place of the transaction Outside of trading venue
2021 DBP Award
Price Volume
Nil 5,314
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 43,815 shares in total
N/A
e)
Date of the transaction
2022-04-29
f)
Place of the transaction
Outside of trading venue
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
a) Name Natalie Walter
2. Reason for the notification
a) Position/status General Counsel
b) Initial notification/ Initial Notification
amendment
3. Details of the Issuer
a) Name Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of 50 pence each
Identification code ISIN: GB00BDFBVT43
b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Long Term Incentive
Plan and Deferred Bonus Plan. No consideration was paid for the grant of
awards.
c) Price(s) and volumes(s) 2022 LTIP Award
Price Volume
Nil 32,268
2021 DBP Award
Price Volume
Nil 14,008
d) Aggregated information
- Aggregate volume Awards granted over 46,276 shares in total
- Price
N/A
e) Date of the transaction 2022-04-29
f) Place of the transaction Outside of trading venue
2021 DBP Award
Price Volume
Nil 14,008
d)
Aggregated information
- Aggregate volume
- Price
Awards granted over 46,276 shares in total
N/A
e)
Date of the transaction
2022-04-29
f)
Place of the transaction
Outside of trading venue
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
a) Name Alexander Lewis
2. Reason for the notification
a) Position/status Chief of Staff
b) Initial notification/ Initial Notification
amendment
3. Details of the Issuer
a) Name Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of 50 pence each
Identification code ISIN: GB00BDFBVT43
b) Nature of the transaction Grant of award over Ordinary Shares under the Company's Long Term Incentive
Plan. No consideration was paid for the grant of awards.
c) Price(s) and volumes(s) 2022 RSU Award
Price Volume
Nil 9,243
d) Aggregated information
- Aggregate volume 9,243
- Price
N/A
e) Date of the transaction 2022-04-29
f) Place of the transaction Outside of trading venue
d)
Aggregated information
- Aggregate volume
- Price
9,243
N/A
e)
Date of the transaction
2022-04-29
f)
Place of the transaction
Outside of trading venue
-Ends-
For further information, please contact:
Oxford Biomedica plc: Tel: +44 (0)1865 783 000
Natalie Walter, Company Secretary
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist
focused on delivering life changing therapies to patients.
Oxford Biomedica plc and its subsidiaries (the Group) work across key viral
vector delivery systems including those based on lentivirus, adeno-associated
virus (AAV) and adenovirus, providing innovative solutions to cell and gene
therapy biotechnology and biopharma companies for their process development,
analytical development and manufacturing needs. Oxford Biomedica has built a
sector leading lentiviral vector delivery system, LentiVector(®) platform,
which the Group leverages to develop product candidates in-house, before
seeking partners to take the products into clinical trials.
Oxford Biomedica is based across several locations and headquartered in
Oxfordshire, UK. In early 2022, the Group established Oxford Biomedica
Solutions, a new US based subsidiary AAV manufacturing and innovation
business, based near Boston, US.
Oxford Biomedica employs more than 940 people. Further information is
available at www.oxb.com (https://www.oxb.com/)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHUPUCGAUPPGQWRecent news on Oxford BioMedica
See all newsREG - Oxford Biomedica PLC - Total Voting Rights
AnnouncementREG - Oxford Biomedica PLC - 2023 Annual Report and Accounts
AnnouncementREG - Oxford Biomedica PLC - Total Voting Rights
AnnouncementREG - Oxford Biomedica PLC - Update on CDMO Services
AnnouncementREG - Oxford Biomedica PLC - Board Changes
Announcement